To determine and investigate the cutaneous side-effects, we clinically examined in forty-two non-small-cell lung cancer patients treated with Gefitinib (Iressa
®), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Twenty-five patients (59.5%) had cutaneous reactions. Frequent adverse events were dry skin (38%), acneiform follicular eruption (33%), seborreheic dermatitis (16.7%), finger scale and fissure (16.7%). In addition, paronychia were found. Dry skin and asteatotic eczema were improved with corticosteroid and moisturizer, acneiform follicular eruption was treated with ibuprofen piconole cream, seborrheic dermatitis was treated with Ketoconazol and corticosteroid cream. Most eruptions were mild (grade 1/2) and improved with those treatments, but 2 patients stopped the medication of Gefinitib because of skin eruptions. The frequency of death between cutaneous reactions group and no eruptions group had no differences.
View full abstract